Blog

Unlocking Insights in Antibody Discovery: An Integrated Approach with the Beacon® Platform and PipeBio

Antibody Discovery / By

Navigating the field of antibody discovery requires a careful balance of innovative methodologies and advanced technologies. Traditional approaches often face limitations due to biases, or risk overlooking critical insights. To overcome these challenges, a recent study delved into harnessing the combined power of Bruker’s Beacon® system and PipeBio software for antigen-specific and cross-reactive antibody discovery. …

Unlocking Insights in Antibody Discovery: An Integrated Approach with the Beacon® Platform and PipeBio Read More »

Application Note: Revolutionizing Adoptive Cell Therapy Development with Bruker’s Beacon® Platform

CAR T Therapy, Cell Therapy, T Cell Profiling / By

Adoptive cell therapy (ACT), the autologous or allogenic transplant of immune cells, is providing new hope in the ongoing battle against cancer. However, the path to harnessing the full potential of these therapies remains challenging, from understanding the intricate dynamics of individual cells to optimizing their therapeutic efficacy. Bruker’s Beacon® Platform emerges as a transformative …

Application Note: Revolutionizing Adoptive Cell Therapy Development with Bruker’s Beacon® Platform Read More »

Exploring Species Diversity in Antibody Discovery on the Beacon® Optofluidic Platform

Antibody Discovery / By

In the continually advancing field of biologics, it’s essential to search for new antibodies with distinct properties. The ability to screen primary B cells across diverse animal species broadens the diversity of recovered antibody sequences and increases the odds of finding the best antibody for any application across reagents, therapeutics, and basic health research. However, …

Exploring Species Diversity in Antibody Discovery on the Beacon® Optofluidic Platform Read More »

Exploring a New Avenue in Vaccine Development: Targeting Conserved Epitopes with Broadly Neutralizing Antibodies

Antibody Discovery / By

SARS-CoV-2’s ability to evolve quickly creates ongoing challenges for vaccine development. The spike protein, critical for the virus’s cell infection, undergoes rapid mutations, making antibodies less effective against new strains. Traditional vaccines, with their lengthy development and testing timelines, struggle to predict these evolutionary changes accurately, leading to a constant struggle to keep pace with …

Exploring a New Avenue in Vaccine Development: Targeting Conserved Epitopes with Broadly Neutralizing Antibodies Read More »

Published in Scientific Reports: Understanding Antibody-Secreting Cells: A Closer Look at Cellular Dynamics with Optofluidic Precision

Antibody Discovery, Infectious Disease, Vaccines / By

The behavior of early-minted antibody-secreting cells (ASC) or plasmablasts post-infection or vaccination plays a pivotal role in the immune response. Traditionally, long-lived plasma cells (LLPC) from the bone marrow are regarded as non-dividing, while blood ASCs are thought to be proliferative. Traditional technologies that average bulk data or measure surface phenotype alone miss critical functional …

Published in Scientific Reports: Understanding Antibody-Secreting Cells: A Closer Look at Cellular Dynamics with Optofluidic Precision Read More »

Published in Frontiers in Molecular Medicine: Revolutionizing CAR-T Cell Manufacturing for Enhanced Therapeutic Responses with Bruker’s Single-Cell Instruments

CAR T Therapy / By

In the rapidly evolving landscape of cancer treatment, chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapeutic approach, garnering FDA approval in 2017. However, the journey from initial success to widespread efficacy has been marked by challenges, prompting researchers to continuously reevaluate and refine CAR-T manufacturing processes. A recent review published …

Published in Frontiers in Molecular Medicine: Revolutionizing CAR-T Cell Manufacturing for Enhanced Therapeutic Responses with Bruker’s Single-Cell Instruments Read More »

Published in Antibody Therapeutics: Alpaca Single B Cell Interrogation and Heavy-Chain-Only Antibody Discovery on the Beacon® Platform

Antibody Discovery / By

Researchers have used Bruker Cellular Analysis’ Optofluidic technology to establish the fastest high-resolution workflow for the discovery and engineering of VHH antibodies yet. Scientists developed a novel application leveraging Bruker’s optofluidic Beacon® platform to detect IgG2/3 antibodies from activated memory B cells derived from alpaca peripheral blood samples. B cells secreting PSMA-specific antibodies were recovered …

Published in Antibody Therapeutics: Alpaca Single B Cell Interrogation and Heavy-Chain-Only Antibody Discovery on the Beacon® Platform Read More »

Bruker Cellular Analysis Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows

Announcement / By

Preliminary SpotLight™ Human Lambda reagent data to be showcased by GSK at the 16th annual PEACe Conference Bruker Cellular Analysis is pleased to announce that GSK will present data on the SpotLight™ Human Lambda reagent for the Beacon® platform at the 16th annual Conference on Protein Expression in Animal Cells, which is being held in Sitges, Spain from September …

Bruker Cellular Analysis Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows Read More »

Revolutionizing Antibody Discovery: How the Beacon Optofluidics System is Saving Time and Resources

Cancer Immunology, Infectious Disease, Inflammation & Neurology, Oncology / By

Biologics have immense commercial potential. However, developing successful candidates can feel like looking for a needle in a haystack. Research, development, manufacturing, and clinical testing are limited by substantial time and cost considerations. But what if you could identify a higher quantity of quality hits in a fraction of the time and with a fraction …

Revolutionizing Antibody Discovery: How the Beacon Optofluidics System is Saving Time and Resources Read More »

Published in Head & Neck: Cytokine Profiling Reveals How Novel Kinase Inhibitor Slows Tumor Cell Growth by Altering Tumor Microenvironment

Cancer Immunology / By

Every year, head and neck cancers (HNC) claim thousands of lives, with over 54,000 cases diagnosed annually in the United States alone, resulting in approximately 11,000 fatalities.1 HNCs are particularly difficult to treat—about one in three patients will not survive five years after diagnosis, despite a range of treatment options including surgery, radiation, chemotherapy, and …

Published in Head & Neck: Cytokine Profiling Reveals How Novel Kinase Inhibitor Slows Tumor Cell Growth by Altering Tumor Microenvironment Read More »